No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important....
Shire is one of those companies that's always rumored to be a buyer or a seller. Not so long ago, it was setting up poison-pill protections against an unwanted suitor. Now, it has beat out Big Pharma with a deal for ViroPharma, the maker of rare disease drugs.
The buyout--at $50 a share--will add Cinryze for hereditary angioedema to Shire's product lineup along with the experimental drug maribavir for cytomegalovirus, one of 8 clinical-stage programs in the pipeline.
Shire is confirming reports that it plans to significantly cut back on its sizeable research operations in Basingstoke, U.K.--another setback for the country's research industry with Novartis axing more than 500 staffers and consultants in Horsham, following major blows from AstraZeneca and Pfizer.
Shire shares spiked to an all-time high after the company revealed new data showing its ADHD drug Vyvanse was effective at treating binge eating disorder.
We know Reckitt Benckiser is shopping its pharma unit. We also know that Shire is scouting for deals. Does it follow that Shire may bid on RB Pharma? Logically, yes. Practically? Maybe.
The diagnosis of attention-deficit hyperactivity disorder keeps growing in the U.S. and drugs to treat it keep going blockbuster. But Europe is another story. And it's a story that Shire has to change if it wants its latest drug in the ADHD lineup to succeed.
The rare-disease drug specialist ViroPharma has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for potential acquisition offers.
The German price watchdog has found yet another drug it can't warm up to. This time it's Shire's new ADHD drug Vyvanse, known as Elvanse in Germany.
AbbVie, Shire and Pfizer are unamused and unimpressed by a designer's use of the names of their drugs Vicodin, Adderall and Xanax as a fashion statement. The new T-shirts have struck a nerve even as regulators are in the midst of a national discussion on prescription drug abuse.